Skip to main content
. Author manuscript; available in PMC: 2019 Feb 20.
Published in final edited form as: AIDS. 2018 Feb 20;32(4):419–429. doi: 10.1097/QAD.0000000000001704

Figure 2. IFNα treatment increases CD16 and CD163 expression on monocytes.

Figure 2

(A–C) HIV-MJ− PBMCs (N=7) were treated with IFNα (50U/mL) for 6, 16, 24 and 48h. (D–F) HIV+MJ− (N=6) and HIV+MJ+ (N=7) PBMCs were treated with IFNα (50U/mL) for 48h. (G–I) Purified CD16− monocytes from HIV-MJ− (N=7) and HIV+MJ− (N=7) donors were treated with IFNα (50U/mL) for 48h. Flow cytometry was used to measure the percentage of CD16+, CD163+ and CD16+CD163+ cells within the monocyte population. *Statistically different from non-stimulated controls (p<0.05, two-way RM ANOVA with a Tukey’s multiple comparisons post-test for A–C and two-way ANOVA with a Sidak’s multiple comparisons test for D–I). Graphs in A–I are mean +/− SEM.